Zobrazeno 1 - 10
of 199
pro vyhledávání: '"Nobuhisa ISHIKAWA"'
Autor:
Takeshi Masuda, Yukari Tsubata, Kojirou Hata, Mika Horie, Katsuyuki Kiura, Nobuhiro Kanaji, Takuya Inoue, Masahiro Kodani, Masaaki Yanai, Kakuhiro Yamaguchi, Naoko Matsumoto, Masahiro Yamasaki, Nobuhisa Ishikawa, Ken Masuda, Nagio Takigawa, Shoichi Kuyama, Tetsuya Kubota, Kazuya Nishii, Katsuyuki Hotta, Noboru Hattori
Publikováno v:
Thoracic Cancer, Vol 15, Iss 34, Pp 2408-2417 (2024)
Abstract Introduction Studies have shown the antitumor efficacy of immune checkpoint inhibitors (ICI) in patients with non‐small cell lung cancer (NSCLC) and brain metastases (BM). However, it is unclear whether the efficacy of ICI is similar betwe
Externí odkaz:
https://doaj.org/article/401e89a484174ad7967a9803e639b733
Autor:
Kosuke Hamai MD, PhD, Ryo Katsura MD, Shinya Miyake MD, Suguru Fujita MD, Shinpei Tada MD, Tetsu Hirakawa MD, Sayaka Ueno MD, Takuya Tanimoto MD, PhD, Nobuhisa Ishikawa MD, PhD
Publikováno v:
Cancer Control, Vol 31 (2024)
Introduction Docetaxel plus ramucirumab (DTX + RAM) therapy is a standard treatment for previously treated lung cancer, but many adverse events have been reported. This retrospective study was conducted to examine if the side effects of DTX + RAM the
Externí odkaz:
https://doaj.org/article/d73842c03f88488690add78a116e86b0
Autor:
Kosuke Hamai, Shinya Miyaka, Shinpei Tada, Suguru Fujita, Tetsu Hirakawa, Mirai Matsumura, Sayaka Ueno, Takuya Tanimoto, Nobuhisa Ishikawa
Publikováno v:
Cancer Reports, Vol 6, Iss 4, Pp n/a-n/a (2023)
Abstract Background Pegfilgrastim is recommended in docetaxel plus ramucirumab (DTX + RAM) therapy for recurrent nonsmall cell lung cancer (NSCLC) because of the associated frequency of febrile neutropenia (FN). However, the FN occurs less frequently
Externí odkaz:
https://doaj.org/article/9bbb937f0fdb497bb48a3030a5bba9c7
Autor:
Takeshi Masuda, Kazunori Fujitaka, Tomoko Suzuki, Kosuke Hamai, Naoko Matsumoto, Mirai Matsumura, Shoko Isoyama, Sayaka Ueno, Mineyo Mito, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Reo Kawano, Ken Masuda, Ryohei Nishino, Nobuhisa Ishikawa, Masahiro Yamasaki, Noboru Hattori
Publikováno v:
Thoracic Cancer, Vol 13, Iss 11, Pp 1611-1618 (2022)
Abstract Background Pembrolizumab is the recommended first‐line therapy for patients with advanced non‐small‐cell lung cancer (NSCLC) and a programmed death ligand‐1 (PD‐L1) tumor proportion score (TPS) of ≥50% without driver mutations. H
Externí odkaz:
https://doaj.org/article/df1f1b43964e4f4284aa4d4a97baabef
Autor:
Naokazu Watari, Kakuhiro Yamaguchi, Hiroaki Terada, Kosuke Hamai, Ken Masuda, Yoshifumi Nishimura, Shinjiro Sakamoto, Takeshi Masuda, Yasushi Horimasu, Shintaro Miyamoto, Taku Nakashima, Hiroshi Iwamoto, Hiroyasu Shoda, Nobuhisa Ishikawa, Kazunori Fujitaka, Kozue Miyazaki, Yoshihiro Miyata, Hironobu Hamada, Kazuo Awai, Noboru Hattori
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Mesenchymal-epithelial transition exon14 (METex14) skipping is one of the therapeutic driver oncogene mutations in non-small cell lung cancer (NSCLC), and can be treated with tepotinib and capmatinib. There is only one report on c
Externí odkaz:
https://doaj.org/article/bece7498093044a7bbb19690580de0ce
Autor:
Yukari Tsubata, Takamasa Hotta, Kosuke Hamai, Naoki Furuya, Toshihide Yokoyama, Ryota Saito, Atsushi Nakamura, Takeshi Masuda, Megumi Hamaguchi, Shoichi Kuyama, Ryoichi Honda, Tadashi Senoo, Masamoto Nakanishi, Masahiro Yamasaki, Nobuhisa Ishikawa, Kazunori Fujitaka, Tetsuya Kubota, Kunihiko Kobayashi, Takeshi Isobe
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-4 (2022)
Abstract Management of cancer-associated venous thromboembolism (VTE) is essential in treatment selection and cancer prognosis. However, to date, there is no method to assess the risk of VTE specifically associated with advanced lung cancer. Our aim
Externí odkaz:
https://doaj.org/article/2fea11230a9f4a7eade6668f5a8337d5
Autor:
Ko Ko, Kazuaki Takahashi, Shintaro Nagashima, Bunthen E, Serge Ouoba, Md Razeen Ashraf Hussain, Tomoyuki Akita, Aya Sugiyama, Takemasa Sakaguchi, Hidetoshi Tahara, Hiroki Ohge, Hideki Ohdan, Tatsuhiko Kubo, Nobuhisa Ishikawa, Toshiro Takafuta, Yoshiki Fujii, Michi Mimori, Fumie Okada, Eisaku Kishita, Kunie Ariyoshi, Masao Kuwabara, Junko Tanaka
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract This study aimed to develop the feasible and effective universal screening strategy of the notable SARS-CoV-2 variants by Sanger Sequencing Strategy and then practically applied it for mass screening in Hiroshima, Japan. A total of 734 sampl
Externí odkaz:
https://doaj.org/article/0f1cf7d725a644ee91f89367d8d92ee2
Autor:
Hisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, Tomonori Makiguchi, Megumi Inaba, Takeshi Honda, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Nobukazu Fujimoto, Yasushi Fukuda, Masayuki Yasugi, Takeshi Tsuda, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: The standard of care for unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC study. Although multiple Japanese phase II studies have shown high effic
Externí odkaz:
https://doaj.org/article/feac51af35784b0ea75161b640b0afa8
Autor:
Yukari Tsubata, Takamasa Hotta, Kosuke Hamai, Naoki Furuya, Toshihide Yokoyama, Ryota Saito, Atsushi Nakamura, Takeshi Masuda, Megumi Hamaguchi, Shoichi Kuyama, Ryoichi Honda, Tadashi Senoo, Masamoto Nakanishi, Masahiro Yamasaki, Nobuhisa Ishikawa, Kazunori Fujitaka, Tetsuya Kubota, Hiroshi Ohtsu, Kunihiko Kobayashi, Takeshi Isobe
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Venous thromboembolism (VTE) is a well-known type of cancer-associated thrombosis and a common complication of malignancy. However, the incidence of VTE associated with lung cancer and the effectiveness of direct oral anticoagulants remai
Externí odkaz:
https://doaj.org/article/800344db585949b3ab355e7763fd895a
Autor:
Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, Megumi Inaba, Ryosuke Ochiai, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Yosuke Miyamoto, Toshihide Yokoyama, Chiaki Matsumoto, Takeshi Tsuda, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: The standard of care for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC trial. Disease progression and pneumonitis were reported as the main rea
Externí odkaz:
https://doaj.org/article/f543356f2cde488fb62f7c3ac3464ba7